Press Releases
2022
February 8 2022
Sanofi completes acquisition of Amunix
2021
December 21, 2021
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
June 23, 2021
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
May 13, 2021
Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.
March 4, 2021
Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline
2020
December 9, 2020
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
September 17, 2020
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
June 22, 2020
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
May 27, 2020
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
March 4, 2020
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
January 10, 2020
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
2019
August 27, 2019
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
June, 26, 2019
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
January 3, 2019
Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors
January 3, 2019
Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform
2018
February 20, 2018
Amunix announces XTEN® and ProTIA technology licensing agreement with Celgene
February 13, 2018
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics & Biosimilars Congress Europe (March 2018)